Jennifer K Lue

Oct 13, 2024 | nature.com | Jennifer K Lue |Alexander P Boardman |Steven Horwitz |Andrew M. Intlekofer |Anita Kumar |Ariela Noy | +4 more

Dear Editor,High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements (HGBCL-DH/TH) is a group of aggressive lymphomas that are associated with poor outcomes when treated with R-CHOP [1, 2]. Conflicting data exists regarding the outcomes of HGBCL with MYC and BCL2 rearrangements (DH-BCL2) as compared to HGBCL with MYC and BCL6 translocations (DH-BCL6) [3,4,5,6].